{
  "id": "589a245a78275d0c4a000026",
  "type": "list",
  "question": "List drug that were evaluated in the CHAMP trial for migraine.",
  "ideal_answer": "Childhood and Adolescent Migraine Prevention (CHAMP) trial evaluated effectiveness of amitriptyline and topiramate in the prevention of migraine in children and adolescents.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/23594025",
    "http://www.ncbi.nlm.nih.gov/pubmed/27039826",
    "http://www.ncbi.nlm.nih.gov/pubmed/27788026"
  ],
  "snippets": [
    {
      "text": "OBJECTIVE: To describe baseline headache characteristics of children and adolescents participating in a multicenter, randomized, double-blinded, placebo-controlled, comparative effectiveness study of amitriptyline, topiramate, and placebo for the prevention of migraine (CHAMP Study).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27039826",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Childhood and Adolescent Migraine Prevention (CHAMP) study: a double-blinded, placebo-controlled, comparative effectiveness study of amitriptyline, topiramate, and placebo in the prevention of childhood and adolescent migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23594025",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "METHODS: CHAMP is a double-blinded, placebo-controlled, multicenter, comparative effectiveness study of amitriptyline and topiramate for the prevention of episodic and chronic migraine, designed to mirror real-world practice, sponsored by the US National Institute of Neurological Disorders and Stroke/National Institutes of Health (U01NS076788). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23594025",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The subjects will be randomized in a 2:2:1 (amitriptyline: topiramate: placebo) ratio. Doses are weight based and will be slowly titrated over an 8-week period to a target dose of 1\u2009mg/kg of amitriptyline and 2\u2009mg/kg of topiramate. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23594025",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: The goal of the CHAMP study is to obtain level 1 evidence for the effectiveness of amitriptyline and topiramate in the prevention of migraine in children and adolescents.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23594025",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "To describe baseline headache characteristics of children and adolescents participating in a multicenter, randomized, double-blinded, placebo-controlled, comparative effectiveness study of amitriptyline, topiramate, and placebo for the prevention of migraine (CHAMP Study).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27039826",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The aim of the Childhood and Adolescent Migraine Prevention (CHAMP) study is to determine the most effective preventive agent to use in children and adolescents.METHODS: CHAMP is a double-blinded, placebo-controlled, multicenter, comparative effectiveness study of amitriptyline and topiramate for the prevention of episodic and chronic migraine, designed to mirror real-world practice, sponsored by the US National Institute of Neurological Disorders and Stroke/National Institutes of Health (U01NS076788).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23594025",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Childhood and Adolescent Migraine Prevention (CHAMP) study: a double-blinded, placebo-controlled, comparative effectiveness study of amitriptyline, topiramate, and placebo in the prevention of childhood and adolescent migraine",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23594025",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The aim of the Childhood and Adolescent Migraine Prevention (CHAMP) study is to determine the most effective preventive agent to use in children and adolescents.CHAMP is a double-blinded, placebo-controlled, multicenter, comparative effectiveness study of amitriptyline and topiramate for the prevention of episodic and chronic migraine, designed to mirror real-world practice, sponsored by the US National Institute of Neurological Disorders and Stroke/National Institutes of Health (U01NS076788)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23594025",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: The goal of the CHAMP study is to obtain level 1 evidence for the effectiveness of amitriptyline and topiramate in the prevention of migraine in children and adolescents. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23594025",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Childhood and Adolescent Migraine Prevention (CHAMP) study: a double-blinded, placebo-controlled, comparative effectiveness study of amitriptyline, topiramate, and placebo in the prevention of childhood and adolescent migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23594025",
      "beginSection": "title",
      "endSection": "title"
    }
  ],
  "concepts": [
    "http://www.disease-ontology.org/api/metadata/DOID:6364",
    "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016430"
  ],
  "exact_answer": "amitriptyline, topiramate"
}